Literature DB >> 11172935

Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease.

S H Kim1, N Cairns, M Fountoulakisc, G Lubec.   

Abstract

Histamine-releasing factor (HRF) stimulates secretion of histamine that is widely distributed in brain and released as neurotransmitter. Several studies suggested that histaminergic deficits could contribute to the cognitive decline in Alzheimer's disease (AD). Based upon deranged histamine metabolism in brain of patients with AD and Down Syndrome (DS), we aimed to study HRF in brain of AD and DS. We used two-dimensional gel electrophoresis, matrix-assisted laser desorption ionization mass spectroscopy and specific software to quantify HRF. HRF was significantly reduced in temporal cortex, thalamus and caudate nucleus of DS and in temporal cortex of AD as compared to controls. This is the first report to show decreased HRF brain levels in DS and AD suggesting the explanation for the decreased cognitive function in neurodegenerative/dementing disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172935     DOI: 10.1016/s0304-3940(01)01545-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

Review 1.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

2.  Immunohistochemical localization of translationally controlled tumor protein in the mouse digestive system.

Authors:  Vadim Sheverdin; Jiwon Jung; Kyunglim Lee
Journal:  J Anat       Date:  2013-07-08       Impact factor: 2.610

3.  Δ9-THC increases endogenous AHA1 expression in rat cerebellum and may modulate CB1 receptor function during chronic use.

Authors:  Catalin M Filipeanu; Jesse J Guidry; Stuart T Leonard; Peter J Winsauer
Journal:  J Neurochem       Date:  2011-08-16       Impact factor: 5.372

4.  Translationally controlled tumour protein (TCTP) is a novel glucose-regulated protein that is important for survival of pancreatic beta cells.

Authors:  F Diraison; K Hayward; K L Sanders; F Brozzi; S Lajus; J Hancock; J E Francis; E Ainscow; U A Bommer; E Molnar; N D Avent; A Varadi
Journal:  Diabetologia       Date:  2010-11-10       Impact factor: 10.122

5.  Histamine H3 Inverse Agonist BF 2649 or Antagonist with Partial H4 Agonist Activity Clobenpropit Reduces Amyloid Beta Peptide-Induced Brain Pathology in Alzheimer's Disease.

Authors:  Ranjana Patnaik; Aruna Sharma; Stephen D Skaper; Dafin F Muresanu; José Vicente Lafuente; Rudy J Castellani; Ala Nozari; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

6.  Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.

Authors:  Lisi Flores-Aguilar; M Florencia Iulita; Olivia Kovecses; Maria D Torres; Sarah M Levi; Yian Zhang; Manor Askenazi; Thomas Wisniewski; Jorge Busciglio; A Claudio Cuello
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

7.  The histamine N-methyltransferase T105I polymorphism affects active site structure and dynamics.

Authors:  Karen Rutherford; W W Parson; Valerie Daggett
Journal:  Biochemistry       Date:  2007-12-23       Impact factor: 3.162

Review 8.  The molecular programme of tumour reversion: the steps beyond malignant transformation.

Authors:  Adam Telerman; Robert Amson
Journal:  Nat Rev Cancer       Date:  2009-01-30       Impact factor: 60.716

9.  Sleep-wake disturbances and frailty in community-living older persons.

Authors:  Carlos A Vaz Fragoso; Evelyne A Gahbauer; Peter H Van Ness; Thomas M Gill
Journal:  J Am Geriatr Soc       Date:  2009-09-30       Impact factor: 5.562

10.  Sumoylation of human translationally controlled tumor protein is important for its nuclear transport.

Authors:  Gnanasekar Munirathinam; Kalyanasundaram Ramaswamy
Journal:  Biochem Res Int       Date:  2012-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.